Ebio1 is a subtype-selective activator of the voltage-gated potassium channel KCNQ2 that enhances conductance through a unique twist-to-open mechanism. It induces conformational changes in the S6 helix, increasing channel activity at a saturating voltage (+50 mV).

CP-100356 hydrochloride is an orally active dual inhibitor of MDR1 (P-gp) and BCRP, with IC50 of ∼0.5 µM for MDR1-mediated calcein-AM transport inhibition and ∼1.5 µM for BCRP-mediated prazosin transport inhibition. It is also a weak inhibitor of OATP1B1 (IC50 ∼ 66 µM).

Ebio1 is a subtype-selective activator of the voltage-gated potassium channel KCNQ2 that enhances conductance through a unique twist-to-open mechanism. It induces conformational changes in the S6 helix, increasing channel activity at a saturating voltage (+50 mV).

Ebio1 is a subtype-selective activator of the voltage-gated potassium channel KCNQ2 that enhances conductance through a unique twist-to-open mechanism. It induces conformational changes in the S6 helix, increasing channel activity at a saturating voltage (+50 mV).

Ebio1 is a subtype-selective activator of the voltage-gated potassium channel KCNQ2 that enhances conductance through a unique twist-to-open mechanism. It induces conformational changes in the S6 helix, increasing channel activity at a saturating voltage (+50 mV).

DDD85646 (IMP-366) is an orally active inhibitor of N-myristoyltransferase(NMT), with an IC50 of 2 nM for Trypanosoma brucei NMT (TbNMT) and 4 nM for human NMT (hNMT). It exhibits a potential for treating human African trypanosomiasis.

DDD85646 (IMP-366) is an orally active inhibitor of N-myristoyltransferase(NMT), with an IC50 of 2 nM for Trypanosoma brucei NMT (TbNMT) and 4 nM for human NMT (hNMT). It exhibits a potential for treating human African trypanosomiasis.

DDD85646 (IMP-366) is an orally active inhibitor of N-myristoyltransferase(NMT), with an IC50 of 2 nM for Trypanosoma brucei NMT (TbNMT) and 4 nM for human NMT (hNMT). It exhibits a potential for treating human African trypanosomiasis.

AZD2389 is a potent, orally active, and selective inhibitor of fibroblast activation protein (FAP) with the potential to treat metabolic dysfunction-associated steatohepatitis.

DDD85646 (IMP-366) is an orally active inhibitor of N-myristoyltransferase(NMT), with an IC50 of 2 nM for Trypanosoma brucei NMT (TbNMT) and 4 nM for human NMT (hNMT). It exhibits a potential for treating human African trypanosomiasis.